The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outpatient practice utilization for CAR-T and T cell engager in patients with lymphoma and multiple myeloma.
 
Radhika Bansal
No Relationships to Disclose
 
Jonas Paludo
Consulting or Advisory Role - Abbvie (Inst)
Research Funding - Biofourmis (Inst); Karyopharm Therapeutics (Inst)
 
Andre De Menezes Silva Corraes
No Relationships to Disclose
 
Spychalla Megan
No Relationships to Disclose
 
Arushi Khurana
No Relationships to Disclose
 
Paul Joseph Hampel
No Relationships to Disclose
 
Urshila Durani
No Relationships to Disclose
 
David Dingli
No Relationships to Disclose
 
Suzanne R. Hayman
No Relationships to Disclose
 
Prashant Kapoor
No Relationships to Disclose
 
Yucai Wang
Employment - Merck (I)
Stock and Other Ownership Interests - Merck (I)
Honoraria - Kite, a Gilead company (Inst)
Consulting or Advisory Role - BeiGene (Inst); Incyte (Inst); Innocare (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Lilly (Inst); Loxo (Inst); TG Therapeutics (Inst)
Research Funding - Genentech (Inst); Genmab (Inst); Incyte (Inst); InnoCare (Inst); Loxo (Inst); MorphoSys (Inst); Novartis (Inst)
 
Moritz Binder
No Relationships to Disclose
 
Taxiarchis Kourelis
No Relationships to Disclose
 
Shaji Kumar
Honoraria - BeiGene; Guangzhou Link Health Pharma; Secura Bio
Consulting or Advisory Role - Abbvie (Inst); Abbvie (Inst); Amgen (Inst); Bluebird Bio (Inst); Celgene (Inst); Genecentrix; Genentech/Roche (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); Molecular Partners (Inst); Oncopeptides; Takeda (Inst)
Research Funding - Abbvie (Inst); CARsgen Therapeutics (Inst); Celgene (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst); TeneoBio (Inst)
 
Rahma M. Warsame
No Relationships to Disclose
 
Nabila Nora Bennani
Consulting or Advisory Role - Acrotech Biopharma (Inst); Affimed Therapeutics (Inst); Daiichi Sankyo (Inst); Kymera (Inst); Kyowa Kirin International (Inst); Secura Bio (Inst); Vividion Therapeutics (Inst)
Research Funding - Vyriad (Inst)
 
Morie A. Gertz
Honoraria - Abbvie; Akcea Therapeutics; Alnylam; Amgen; Apellis Pharmaceuticals; Celgene; Janssen Oncology; Juno/Celgene; Med Learning Group; Prothena; Research to Practice; Sanofi; Telix Pharmaceuticals
Consulting or Advisory Role - Bristol-Myers Squibb/Sanofi; Prothena
Travel, Accommodations, Expenses - Celgene; Novartis; Prothena
 
Patrick B. Johnston
No Relationships to Disclose
 
Stephen M. Ansell
No Relationships to Disclose
 
Yi Lin
Consulting or Advisory Role - Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Gamida Cell (Inst); Janssen Oncology (Inst); Juno Therapeutics (Inst); Kite/Gilead (Inst); Legend Biotech (Inst); Novartis (Inst); Pfizer (Inst); Sorrento Therapeutics (Inst); Vineti (Inst)
Research Funding - Bluebird Bio (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Merck (Inst); Takeda (Inst)